Nrf2 - A therapeutic target for the treatment of neurodegenerative diseases

Free Radical Biology and Medicine

Volumn 88, Issue Part B, 2015, Pages 253-267

  Johnson, Delinda A ^a   Johnson, Jeffrey A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Huntington's disease; Multiple sclerosis; Nrf2; Oxidative stress; Parkinson's disease

Indexed keywords

BIOLOGICAL MARKER; TRANSCRIPTION FACTOR NRF2;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT RESPONSIVE ELEMENT; DEGENERATIVE DISEASE; DISEASE COURSE; DNA MODIFICATION; ENVIRONMENTAL FACTOR; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN HOMEOSTASIS; PROTEIN MODIFICATION; REVIEW; RISK FACTOR; ANIMAL; BRAIN; METABOLISM; OXIDATION REDUCTION REACTION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN; HUMANS; NEURODEGENERATIVE DISEASES; NF-E2-RELATED FACTOR 2; OXIDATION-REDUCTION; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84969884761     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2015.07.147     Document Type: Review

References (229)

1. M. Valko, D. Leibfritz, J. Moncol, M.T. Cronin, M. Mazur, and J. Telser Free radicals and antioxidants in normal physiological functions and human disease Int J Biochem Cell Biol 39 2007 44 84
2. K. Dasuri, L. Zhang, and J.N. Keller Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis Free Radic Biol Med 2012
3. D.T. Dexter, C.J. Carter, F.R. Wells, F. Javoy-Agid, Y. Agid, A. Lees, P. Jenner, and C.D. Marsden Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease J Neurochem 52 1989 381 389
4. D.T. Dexter, A.E. Holley, W.D. Flitter, T.F. Slater, F.R. Wells, S.E. Daniel, A.J. Lees, P. Jenner, and C.D. Marsden Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study Mov Disord 9 1994 92 97
5. A. Yoritaka, N. Hattori, K. Uchida, M. Tanaka, E.R. Stadtman, and Y. Mizuno Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease Proc Natl Acad Sci U S A 93 1996 2696 2701
6. Y. Ando, T. Brannstrom, K. Uchida, N. Nyhlin, B. Nasman, O. Suhr, T. Yamashita, T. Olsson, M. El Salhy, M. Uchino, and M. Ando Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid J Neurol Sci 156 1998 172 176
7. W.R. Markesbery, and M.A. Lovell Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease Neurobiol Aging 19 1998 33 36
8. T.I. Williams, B.C. Lynn, W.R. Markesbery, and M.A. Lovell Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease Neurobiol Aging 27 2006 1094 1099
9. R.G. Smith, Y.K. Henry, M.P. Mattson, and S.H. Appel Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis Ann Neurol 44 1998 696 699
10. E.P. Simpson, Y.K. Henry, J.S. Henkel, R.G. Smith, and S.H. Appel Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden Neurology 62 2004 1758 1765
11. K.S. Montine, P.J. Kim, S.J. Olson, W.R. Markesbery, and T.J. Montine 4-hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease J Neuropathol Exp Neurol 56 1997 866 871
12. L.M. Sayre, D.A. Zelasko, P.L. Harris, G. Perry, R.G. Salomon, and M.A. Smith 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease J Neurochem 68 1997 2092 2097
13. W.A. Pedersen, W. Fu, J.N. Keller, W.R. Markesbery, S. Appel, R.G. Smith, E. Kasarskis, and M.P. Mattson Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients Ann Neurol 44 1998 819 824
14. Z.I. Alam, S.E. Daniel, A.J. Lees, D.C. Marsden, P. Jenner, and B. Halliwell A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease J Neurochem 69 1997 1326 1329
15. E. Floor, and M.G. Wetzel Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay J Neurochem 70 1998 268 275
16. M.Y. Aksenov, M.V. Aksenova, D.A. Butterfield, J.W. Geddes, and W.R. Markesbery Protein oxidation in the brain in Alzheimer's disease Neuroscience 103 2001 373 383
17. M.F. Beal Oxidatively modified proteins in aging and disease' Free Radic Biol Med 32 2002 797 803
18. A.C. Bowling, J.B. Schulz, R.H. Brown Jr., and M.F. Beal Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis J Neurochem 61 1993 2322 2325
19. K. Hensley, N. Hall, R. Subramaniam, P. Cole, M. Harris, M. Aksenov, M. Aksenova, S.P. Gabbita, J.F. Wu, J.M. Carney, and et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation J Neurochem 65 1995 2146 2156
20. L. Lyras, N.J. Cairns, A. Jenner, P. Jenner, and B. Halliwell An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease J Neurochem 68 1997 2061 2069
21. R. Pamplona, E. Dalfo, V. Ayala, M.J. Bellmunt, J. Prat, I. Ferrer, and M. Portero-Otin Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets' J Biol Chem 280 2005 21522 21530
22. Z.I. Alam, A. Jenner, S.E. Daniel, A.J. Lees, N. Cairns, C.D. Marsden, P. Jenner, and B. Halliwell Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra J Neurochem 69 1997 1196 1203
23. M.C. Polidori, P. Mecocci, S.E. Browne, U. Senin, and M.F. Beal Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex Neurosci Lett 272 1999 53 56
24. N. Shibata, R. Nagai, S. Miyata, T. Jono, S. Horiuchi, A. Hirano, S. Kato, S. Sasaki, K. Asayama, and M. Kobayashi Nonoxidative protein glycation is implicated in familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation Acta Neuropathol 100 2000 275 284
25. M.A. Lovell, and W.R. Markesbery Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid Arch Neurol 58 2001 392 396
26. A. Kikuchi, A. Takeda, H. Onodera, T. Kimpara, K. Hisanaga, N. Sato, A. Nunomura, R.J. Castellani, G. Perry, M.A. Smith, and Y. Itoyama Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy Neurobiol Dis 9 2002 244 248
27. Y. Ihara, K. Nobukuni, H. Takata, and T. Hayabara Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Zn-superoxide dismutase mutation Neurol Res 27 2005 105 108
28. C.M. Chen, Y.R. Wu, M.L. Cheng, J.L. Liu, Y.M. Lee, P.W. Lee, B.W. Soong, and D.T. Chiu Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients Biochem Biophys Res Commun 359 2007 335 340
29. T. Murata, C. Ohtsuka, and Y. Terayama Increased mitochondrial oxidative damage and oxidative DNA damage contributes to the neurodegenerative process in sporadic amyotrophic lateral sclerosis Free Radic Res 42 2008 221 225
30. O. Zengi, A. Karakas, U. Ergun, M. Senes, L. Inan, and D. Yucel Urinary 8-hydroxy-2'-deoxyguanosine level and plasma paraoxonase 1 activity with Alzheimer's disease Clin Chem Lab Med 50 2012 529 534
31. B.I. Giasson, J.E. Duda, I.V. Murray, Q. Chen, J.M. Souza, H.I. Hurtig, H. Ischiropoulos, J.Q. Trojanowski, and V.M. Lee Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions Science 290 2000 985 989
32. H. Shimura, M.G. Schlossmacher, N. Hattori, M.P. Frosch, A. Trockenbacher, R. Schneider, Y. Mizuno, K.S. Kosik, and D.J. Selkoe Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease Science 293 2001 263 269
33. H. Fujiwara, M. Hasegawa, N. Dohmae, A. Kawashima, E. Masliah, M.S. Goldberg, J. Shen, K. Takio, and T. Iwatsubo alpha-Synuclein is phosphorylated in synucleinopathy lesions Nat Cell Biol 4 2002 160 164
34. G.T. Bramblett, J.Q. Trojanowski, and V.M. Lee Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding-competent tau and accumulation of abnormal tau-isoforms (A68 proteins) Lab Invest 66 1992 212 222
35. T. Horiguchi, K. Uryu, B.I. Giasson, H. Ischiropoulos, R. LightFoot, C. Bellmann, C. Richter-Landsberg, V.M. Lee, and J.Q. Trojanowski Nitration of tau protein is linked to neurodegeneration in tauopathies Am J Pathol 163 2003 1021 1031
36. M.A. Smith, P.L. Richey Harris, L.M. Sayre, J.S. Beckman, and G. Perry Widespread peroxynitrite-mediated damage in Alzheimer's disease J Neurosci 17 1997 2653 2657
37. K. Hensley, M.L. Maidt, Z. Yu, H. Sang, W.R. Markesbery, and R.A. Floyd Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation J Neurosci 18 1998 8126 8132
38. T.H. Rushmore, and C.B. Pickett Transcriptional regulation of the rat glutathione S-transferase Ya subunit gene. Characterization of a xenobiotic-responsive element controlling inducible expression by phenolic antioxidants J Biol Chem 265 1990 14648 14653
39. T.H. Rushmore, M.R. Morton, and C.B. Pickett The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity J Biol Chem 266 1991 11632 11639
40. K. Itoh, N. Wakabayashi, Y. Katoh, T. Ishii, K. Igarashi, J.D. Engel, and M. Yamamoto Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain Genes Dev 13 1999 76 86
41. L.M. Zipper, and R.T. Mulcahy The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm' J Biol Chem 277 2002 36544 36552
42. K. Itoh, N. Wakabayashi, Y. Katoh, T. Ishii, T. O'Connor, and M. Yamamoto Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles Genes Cells 8 2003 379 391
43. M. McMahon, K. Itoh, M. Yamamoto, and J.D. Hayes Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression J Biol Chem 278 2003 21592 21600
44. T.W. Kensler, N. Wakabayashi, and S. Biswal Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway Annu Rev Pharmacol Toxicol 47 2007 89 116
45. G.P. Sykiotis, and D. Bohmann Stress-activated cap'n'collar transcription factors in aging and human disease Sci Signal 2010 3: re3
46. D.D. Zhang Mechanistic studies of the Nrf2-Keap1 signaling pathway Drug Metab Rev 38 2006 769 789
47. A.T. Dinkova-Kostova, W.D. Holtzclaw, R.N. Cole, K. Itoh, N. Wakabayashi, Y. Katoh, M. Yamamoto, and P. Talalay Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants Proc Natl Acad Sci U S A 99 2002 11908 11913
48. K.I. Tong, A. Kobayashi, F. Katsuoka, and M. Yamamoto Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism Biol Chem 387 2006 1311 1320
49. K.I. Tong, Y. Katoh, H. Kusunoki, K. Itoh, T. Tanaka, and M. Yamamoto Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model Mol Cell Biol 26 2006 2887 2900
50. P. Rada, A.I. Rojo, S. Chowdhry, M. McMahon, J.D. Hayes, and A. Cuadrado SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner Mol Cell Biol 31 2011 1121 1133
51. T. Wu, F. Zhao, B. Gao, C. Tan, N. Yagishita, T. Nakajima, P.K. Wong, E. Chapman, D. Fang, and D.D. Zhang Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis Genes Dev 28 2014 708 722
52. Y. Liu, J.T. Kern, J.R. Walker, J.A. Johnson, P.G. Schultz, and H. Luesch A genomic screen for activators of the antioxidant response element Proc Natl Acad Sci U S A 104 2007 5205 5210
53. M. Komatsu, H. Kurokawa, S. Waguri, K. Taguchi, A. Kobayashi, Y. Ichimura, Y.S. Sou, I. Ueno, A. Sakamoto, K.I. Tong, M. Kim, Y. Nishito, S.I. Iemura, T. Natsume, T. Ueno, E. Kominami, H. Motohashi, K. Tanaka, and M. Yamamoto The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1 Nat Cell Biol. 2010
54. B.E. Hast, D. Goldfarb, K.M. Mulvaney, M.A. Hast, P.F. Siesser, F. Yan, D.N. Hayes, and M.B. Major Proteomic analysis of ubiquitin ligase Keap1 reveals associated proteins that inhibit Nrf2 ubiquitination Cancer Res 73 2013 2199 2210
55. W. Chen, Z. Sun, X.J. Wang, T. Jiang, Z. Huang, D. Fang, and D.D. Zhang Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response Mol Cell 34 2009 663 673
56. N.D. Camp, R.G. James, D.W. Dawson, F. Yan, J.M. Davison, S.A. Houck, X. Tang, N. Zheng, M.B. Major, and R.T. Moon Wilms tumor gene on X chromosome (WTX) inhibits degradation of Nrf2 protein through competitive binding to Keap1 protein J Biol Chem 287 2012 6539 6550
57. J. Ma, H. Cai, T. Wu, B. Sobhian, Y. Huo, A. Alcivar, M. Mehta, K.L. Cheung, S. Ganesan, A.N. Kong, D.D. Zhang, and B. Xia PALB2 interacts with Keap1 to promote Nrf2 nuclear accumulation and function Mol Cell Biol 32 2012 1506 1517
58. Alzheimer'sAssociation 2014 Alzheimer's disease facts and figures Alzheimers Dement 10 2014 e47 e92
59. W.L. Klein, G.A. Krafft, and C.E. Finch Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 24 2001 219 224
60. R. Sandbrink, T. Hartmann, C.L. Masters, and K. Beyreuther Genes contributing to Alzheimer's disease Mol Psychiatry 1 1996 27 40
61. A.K. Raina, D.J. Templeton, J.C. Deak, G. Perry, and M.A. Smith Quinone reductase (NQO1), a sensitive redox indicator, is increased in Alzheimer's disease Redox Rep 4 1999 23 27
62. Y. Wang, K. Santa-Cruz, C. DeCarli, and J.A. Johnson NAD(P)H:quinone oxidoreductase activity is increased in hippocampal pyramidal neurons of patients with Aalzheimer's disease Neurobiol Aging 21 2000 525 531
63. K.S. SantaCruz, E. Yazlovitskaya, J. Collins, J. Johnson, and C. DeCarli Regional NAD(P)H:quinone oxidoreductase activity in Alzheimer's disease Neurobiol Aging 25 2004 63 69
64. H.M. Schipper, S. Cisse, and E.G. Stopa Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain Ann Neurol 37 1995 758 768
65. H.M. Schipper, H. Chertkow, K. Mehindate, D. Frankel, C. Melmed, and H. Bergman Evaluation of heme oxygenase-1 as a systemic biological marker of sporadic AD Neurology 54 2000 1297 1304
66. M.Y. Aksenov, and W.R. Markesbery Changes in thiol content and expression of glutathione redox system genes in the hippocampus and cerebellum in Alzheimer's disease Neurosci Lett 302 2001 141 145
67. K. Tanji, A. Maruyama, S. Odagiri, F. Mori, K. Itoh, A. Kakita, H. Takahashi, and K. Wakabayashi Keap1 is localized in neuronal and glial cytoplasmic inclusions in various neurodegenerative diseases J Neuropathol Exp Neurol 72 2013 18 28
68. C.P. Ramsey, C.A. Glass, M.B. Montgomery, K.A. Lindl, G.P. Ritson, L.A. Chia, R.L. Hamilton, C.T. Chu, and K.L. Jordan-Sciutto Expression of Nrf2 in neurodegenerative diseases J Neuropathol Exp Neurol 66 2007 75 85
69. M.A. Lovell, C. Xie, and W.R. Markesbery Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease Neurology 51 1998 1562 1566
70. M.A. Ansari, and S.W. Scheff Oxidative stress in the progression of Alzheimer disease in the frontal cortex J Neuropathol Exp Neurol 69 2010 155 167
71. S. Saharan, and P.K. Mandal The emerging role of glutathione in Alzheimer's disease J Alzheimers Dis 40 2014 519 529
72. A.D. Kraft, J.M. Lee, D.A. Johnson, Y.W. Kan, and J.A. Johnson Neuronal sensitivity to kainic acid is dependent on the Nrf2-mediated actions of the antioxidant response element J Neurochem 98 2006 1852 1865
73. G. Joshi, K.A. Gan, D.A. Johnson, and J.A. Johnson Increased Alzheimer's disease-like pathology in the APP/ PS1DeltaE9 mouse model lacking Nrf2 through modulation of autophagy Neurobiol Aging 36 2015 664 679
74. K. Kanninen, T.M. Malm, H.K. Jyrkkanen, G. Goldsteins, V. Keksa-Goldsteine, H. Tanila, M. Yamamoto, S. Yla-Herttuala, A.L. Levonen, and J. Koistinaho Nuclear factor erythroid 2-related factor 2 protects against beta amyloid Mol Cell Neurosci 39 2008 302 313
75. V. Torres-Lista, C. Parrado-Fernandez, I. Alvarez-Monton, J. Frontinan-Rubio, M. Duran-Prado, J.R. Peinado, B. Johansson, F.J. Alcain, and L. Gimenez-Llort Neophobia, NQO1 and SIRT1 as premorbid and prodromal indicators of AD in 3xTg-AD mice Behav Brain Res 271 2014 140 146
76. S.I. Mota, R.O. Costa, I.L. Ferreira, I. Santana, G.L. Caldeira, C. Padovano, A.C. Fonseca, I. Baldeiras, C. Cunha, L. Letra, C.R. Oliveira, C.M. Pereira, and A.C. Rego Oxidative stress involving changes in Nrf2 and ER stress in early stages of Alzheimer's disease Biochim Biophys Acta. 2015
77. A. Jain, T. Lamark, E. Sjottem, K.B. Larsen, J.A. Awuh, A. Overvatn, M. McMahon, J.D. Hayes, and T. Johansen.'p62/SQSTM1 is a target gene for transcription factor Nrf2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription J Biol Chem 285 2010 22576 22591
78. B.E. Riley, S.E. Kaiser, and R.R. Kopito Autophagy inhibition engages Nrf2-p62 Ub-associated signaling Autophagy 7 2010 338 340
79. K. Fujita, D. Maeda, Q. Xiao, and S.M. Srinivasula Nrf2-mediated induction of p62 controls Toll-like receptor-4-driven aggresome-like induced structure formation and autophagic degradation Proc Natl Acad Sci U S A 108 2011 1427 1432
80. C. Jo, S. Gundemir, S. Pritchard, Y.N. Jin, I. Rahman, and G.V. Johnson Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52 Nat Commun 5 2014 3496
81. S.A. Farr, J.L. Ripley, R. Sultana, Z. Zhang, M.L. Niehoff, T.L. Platt, M.P. Murphy, J.E. Morley, V. Kumar, and D.A. Butterfield Antisense oligonucleotide against GSK-3beta in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease Free Radic Biol Med 67 2014 387 395
82. K. Kanninen, R. Heikkinen, T. Malm, T. Rolova, S. Kuhmonen, H. Leinonen, S. Yla-Herttuala, H. Tanila, A.L. Levonen, M. Koistinaho, and J. Koistinaho Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease Proc Natl Acad Sci U S A 106 2009 16505 16510
83. A.Y. Shih, D.A. Johnson, G. Wong, A.D. Kraft, L. Jiang, H. Erb, J.A. Johnson, and T.H. Murphy Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress J Neurosci 23 2003 3394 3406
84. A.D. Kraft, D.A. Johnson, and J.A. Johnson Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult J Neurosci 24 2004 1101 1112
85. M.R. Vargas, D.A. Johnson, D.W. Sirkis, A. Messing, and J.A. Johnson Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis J Neurosci 28 2008 13574 13581
86. M. Dumont, E. Wille, N.Y. Calingasan, D. Tampellini, C. Williams, G.K. Gouras, K. Liby, M. Sporn, C. Nathan, M. Flint Beal, and M.T. Lin Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease J Neurochem 109 2009 502 512
87. Y. Zhou, N. Xie, L. Li, Y. Zou, X. Zhang, and M. Dong Puerarin alleviates cognitive impairment and oxidative stress in APP/PS1 transgenic mice Int J Neuropsychopharmacol 17 2014 635 644
88. M. Leiros, E. Alonso, M.E. Rateb, W.E. Houssen, R. Ebel, M. Jaspars, A. Alfonso, and L.M. Botana Gracilins: Spongionella-derived promising compounds for Alzheimer disease Neuropharmacology 93 2015 285 293
89. S. Jeon, J. Hur, H.J. Jeong, B.S. Koo, and S.C. Pak SuHeXiang Wan essential oil alleviates amyloid beta induced memory impairment through inhibition of tau protein phosphorylation in mice Am J Chin Med 39 2011 917 932
90. H.V. Kim, H.Y. Kim, H.Y. Ehrlich, S.Y. Choi, D.J. Kim, and Y. Kim Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model Amyloid 20 2013 7 12
91. R. Zhang, Q.W. Miao, C.X. Zhu, Y. Zhao, L. Liu, J. Yang, and L. An Sulforaphane Ameliorates Neurobehavioral Deficits and Protects the Brain From Amyloid beta Deposits and Peroxidation in Mice With Alzheimer-Like Lesions Am J Alzheimers Dis Other Demen 30 2015 183 191
92. G. Xie, W. Tian, T. Wei, and F. Liu The neuroprotective effects of beta-hydroxybutyrate on Abeta-injected rat hippocampus in vivo and in Abeta-treated PC-12 cells in vitro Free Radic Res 49 2015 139 150
93. L. Yu, S. Wang, X. Chen, H. Yang, X. Li, Y. Xu, and X. Zhu Orientin alleviates cognitive deficits and oxidative stress in Abeta1-42-induced mouse model of Alzheimer's disease Life Sci 121 2015 104 109
94. C. Chen, X. Li, P. Gao, Y. Tu, M. Zhao, J. Li, S. Zhang, and H. Liang Baicalin attenuates alzheimer-like pathological changes and memory deficits induced by amyloid beta1-42 protein Metab Brain Dis 30 2015 537 544
95. M.F. Beal Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease Parkinsonism Relat Disord 15 Suppl 3 2009 S189 S194
96. M.G. Spillantini, M.L. Schmidt, V.M. Lee, J.Q. Trojanowski, R. Jakes, and M. Goedert Alpha-synuclein in Lewy bodies Nature 388 1997 839 840
97. M.C. Irizarry, W. Growdon, T. Gomez-Isla, K. Newell, J.M. George, D.F. Clayton, and B.T. Hyman Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity J Neuropathol Exp Neurol 57 1998 334 337
98. M.G. Spillantini, R.A. Crowther, R. Jakes, M. Hasegawa, and M. Goedert alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies Proc Natl Acad Sci U S A 95 1998 6469 6473
99. A. Samii, J.G. Nutt, and B.R. Ransom Parkinson's disease Lancet 363 2004 1783 1793
100. S. Lesage, and A. Brice Parkinson's disease: from monogenic forms to genetic susceptibility factors Hum Mol Genet 18 2009 R48 R59
101. F.L. van Muiswinkel, R.A. de Vos, J.G. Bol, G. Andringa, E.N. Jansen Steur, D. Ross, D. Siegel, and B. Drukarch Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra Neurobiol Aging 25 2004 1253 1262
102. R. Castellani, M.A. Smith, P.L. Richey, and G. Perry Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease Brain Res 737 1996 195 200
103. H.M. Schipper, A. Liberman, and E.G. Stopa Neural heme oxygenase-1 expression in idiopathic Parkinson's disease Exp Neurol 150 1998 60 68
104. M. Basso, S. Giraudo, D. Corpillo, B. Bergamasco, L. Lopiano, and M. Fasano Proteome analysis of human substantia nigra in Parkinson's disease Proteomics 4 2004 3943 3952
105. T.L. Perry, and V.W. Yong Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients Neurosci Lett 67 1986 269 274
106. G.D. Zeevalk, R. Razmpour, and L.P. Bernard Glutathione and Parkinson's disease: is this the elephant in the room Biomed Pharmacother 62 2008 236 249
107. Y. Imaizumi, Y. Okada, W. Akamatsu, M. Koike, N. Kuzumaki, H. Hayakawa, T. Nihira, T. Kobayashi, M. Ohyama, S. Sato, M. Takanashi, M. Funayama, A. Hirayama, T. Soga, T. Hishiki, M. Suematsu, T. Yagi, D. Ito, A. Kosakai, K. Hayashi, M. Shouji, A. Nakanishi, N. Suzuki, Y. Mizuno, N. Mizushima, M. Amagai, Y. Uchiyama, H. Mochizuki, N. Hattori, and H. Okano Mitochondrial dysfunction associated with increased oxidative stress and alpha-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue Mol Brain 5 2012 35
108. P.C. Chen, M.R. Vargas, A.K. Pani, R.J. Smeyne, D.A. Johnson, Y.W. Kan, and J.A. Johnson Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte Proc Natl Acad Sci U S A 106 2009 2933 2938
109. D.A. Johnson, G.K. Andrews, W. Xu, and J.A. Johnson Activation of the antioxidant response element in primary cortical neuronal cultures derived from transgenic reporter mice J Neurochem 81 2002 1233 1241
110. A. Minelli, C. Conte, I. Cacciatore, C. Cornacchia, and F. Pinnen Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to L: -dopa in a Parkinson's animal model Amino Acids. 2012
111. N.G. Innamorato, A. Jazwa, A.I. Rojo, C. Garcia, J. Fernandez-Ruiz, A. Grochot-Przeczek, A. Stachurska, A. Jozkowicz, J. Dulak, and A. Cuadrado Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1 PLoS One 5 2010 e11838
112. C. Lu, J. Zhang, X. Shi, S. Miao, L. Bi, S. Zhang, Q. Yang, X. Zhou, M. Zhang, Y. Xie, Q. Miao, and S. Wang Neuroprotective effects of tetramethylpyrazine against dopaminergic neuron injury in a rat model of Parkinson's disease induced by MPTP Int J Biol Sci 10 2014 350 357
113. Y.H. Tsou, C.T. Shih, C.H. Ching, J.Y. Huang, C.J. Jen, L. Yu, Y.M. Kuo, F.S. Wu, and J.I. Chuang Treadmill exercise activates Nrf2 antioxidant system to protect the nigrostriatal dopaminergic neurons from MPP+ toxicity Exp Neurol 263 2015 50 62
114. R.J. Jakel, J.T. Kern, D.A. Johnson, and J.A. Johnson Induction of the protective antioxidant response element pathway by 6-hydroxydopamine in vivo and in vitro Toxicol Sci 87 2005 176 186
115. R. Li, T. Liang, L. Xu, N. Zheng, K. Zhang, and X. Duan Puerarin attenuates neuronal degeneration in the substantia nigra of 6-OHDA-lesioned rats through regulating BDNF expression and activating the Nrf2/ARE signaling pathway Brain Res 1523 2013 1 9
116. L. Gan, M.R. Vargas, D.A. Johnson, and J.A. Johnson Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model J Neurosci 32 2012 17775 17787
117. D. Beraud, H.A. Hathaway, J. Trecki, S. Chasovskikh, D.A. Johnson, J.A. Johnson, H.J. Federoff, M. Shimoji, T.R. Mhyre, and K.A. Maguire-Zeiss Microglial activation and antioxidant responses induced by the Parkinson's disease protein alpha-synuclein J Neuroimmune Pharmacol 8 2013 94 117
118. N.C. Burton, T.W. Kensler, and T.R. Guilarte In vivo modulation of the Parkinsonian phenotype by Nrf2 Neurotoxicology 27 2006 1094 1100
119. R.J. Jakel, J.A. Townsend, A.D. Kraft, and J.A. Johnson Nrf2-mediated protection against 6-hydroxydopamine Brain Res 1144 2007 192 201
120. A.I. Rojo, N.G. Innamorato, A.M. Martin-Moreno, M.L. De Ceballos, M. Yamamoto, and A. Cuadrado Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease Glia 58 2010 588 598
121. A. Jazwa, A.I. Rojo, N.G. Innamorato, M. Hesse, J. Fernandez-Ruiz, and A. Cuadrado Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism Antioxid Redox Signal 14 2011 2347 2360
122. N.A. Kaidery, R. Banerjee, L. Yang, N.A. Smirnova, D.M. Hushpulian, K.T. Liby, C.R. Williams, M. Yamamoto, T.W. Kensler, R.R. Ratan, M.B. Sporn, M.F. Beal, I.G. Gazaryan, and B. Thomas Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease Antioxid Redox Signal 18 2013 139 157
123. I. Lastres-Becker, A. Ulusoy, N.G. Innamorato, G. Sahin, A. Rabano, D. Kirik, and A. Cuadrado alpha-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease Hum Mol Genet 21 2012 3173 3192
124. L.P. Rowland, and N.A. Shneider Amyotrophic lateral sclerosis N Engl J Med 344 2001 1688 1700
125. S. Murayama, Y. Ookawa, H. Mori, I. Nakano, Y. Ihara, S. Kuzuhara, and M. Tomonaga Immunocytochemical and ultrastructural study of Lewy body-like hyaline inclusions in familial amyotrophic lateral sclerosis Acta Neuropathol 78 1989 143 152
126. Y. Mizuno, M. Amari, M. Takatama, H. Aizawa, B. Mihara, and K. Okamoto Immunoreactivities of p62, an ubiqutin-binding protein, in the spinal anterior horn cells of patients with amyotrophic lateral sclerosis J Neurol Sci 249 2006 13 18
127. C.F. Tan, H. Eguchi, A. Tagawa, O. Onodera, T. Iwasaki, A. Tsujino, M. Nishizawa, A. Kakita, and H. Takahashi TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation Acta Neuropathol 113 2007 535 542
128. C. Vance, B. Rogelj, T. Hortobagyi, K.J. De Vos, A.L. Nishimura, J. Sreedharan, X. Hu, B. Smith, D. Ruddy, P. Wright, J. Ganesalingam, K.L. Williams, V. Tripathi, S. Al-Saraj, A. Al-Chalabi, P.N. Leigh, I.P. Blair, G. Nicholson, J. de Belleroche, J.M. Gallo, C.C. Miller, and C.E. Shaw Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6 Science 323 2009 1208 1211
129. D.R. Rosen, T. Siddique, D. Patterson, D.A. Figlewicz, P. Sapp, A. Hentati, D. Donaldson, J. Goto, J.P. O'Regan, H.X. Deng, and et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis Nature 362 1993 59 62
130. M.E. Gurney, H. Pu, A.Y. Chiu, M.C. Dal Canto, C.Y. Polchow, D.D. Alexander, J. Caliendo, A. Hentati, Y.W. Kwon, H.X. Deng, and et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation Science 264 1994 1772 1775
131. D.S. Howland, J. Liu, Y. She, B. Goad, N.J. Maragakis, B. Kim, J. Erickson, J. Kulik, L. DeVito, G. Psaltis, L.J. DeGennaro, D.W. Cleveland, and J.D. Rothstein Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS) Proc Natl Acad Sci U S A 99 2002 1604 1609
132. A.M. Clement, M.D. Nguyen, E.A. Roberts, M.L. Garcia, S. Boillee, M. Rule, A.P. McMahon, W. Doucette, D. Siwek, R.J. Ferrante, R.H. Brown Jr., J.P. Julien, L.S. Goldstein, and D.W. Cleveland Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice Science 302 2003 113 117
133. G. Marangi, and B.J. Traynor Genetic causes of amyotrophic lateral sclerosis: New genetic analysis methodologies entailing new opportunities and challenges Brain Res 1607 2015 75 93
134. F. Fecto, J. Yan, S.P. Vemula, E. Liu, Y. Yang, W. Chen, J.G. Zheng, Y. Shi, N. Siddique, H. Arrat, S. Donkervoort, S. Ajroud-Driss, R.L. Sufit, S.L. Heller, H.X. Deng, and T. Siddique SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis Arch Neurol 68 2011 1440 1446
135. A. Sarlette, K. Krampfl, C. Grothe, N. Neuhoff, R. Dengler, and S. Petri Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis J Neuropathol Exp Neurol 67 2008 1055 1062
136. M.R. Vargas, M. Pehar, P. Cassina, L. Martinez-Palma, J.A. Thompson, J.S. Beckman, and L. Barbeito Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes: consequences for motor neuron survival J Biol Chem 280 2005 25571 25579
137. M.R. Vargas, M. Pehar, P. Cassina, J.S. Beckman, and L. Barbeito Increased glutathione biosynthesis by Nrf2 activation in astrocytes prevents p75NTR-dependent motor neuron apoptosis J Neurochem 97 2006 687 696
138. M. Pehar, M.R. Vargas, K.M. Robinson, P. Cassina, P.J. Diaz-Amarilla, T.M. Hagen, R. Radi, L. Barbeito, and J.S. Beckman Mitochondrial superoxide production and nuclear factor erythroid 2-related factor 2 activation in p75 neurotrophin receptor-induced motor neuron apoptosis J Neurosci 27 2007 7777 7785
139. T. Mimoto, K. Miyazaki, N. Morimoto, T. Kurata, K. Satoh, Y. Ikeda, and K. Abe Impaired antioxydative Keap1/Nrf2 system and the downstream stress protein responses in the motor neuron of ALS model mice Brain Res 1446 2012 109 118
140. Y. Guo, Y. Zhang, D. Wen, W. Duan, T. An, P. Shi, J. Wang, Z. Li, X. Chen, and C. Li The modest impact of transcription factor Nrf2 on the course of disease in an ALS animal model Lab Invest 93 2013 825 833
141. A.D. Kraft, J.M. Resch, D.A. Johnson, and J.A. Johnson Activation of the Nrf2-ARE pathway in muscle and spinal cord during ALS-like pathology in mice expressing mutant SOD1 Exp Neurol 207 2007 107 117
142. M.R. Vargas, N.C. Burton, J. Kutzke, L. Gan, D.A. Johnson, M. Schafer, S. Werner, and J.A. Johnson Absence of Nrf2 or its selective overexpression in neurons and muscle does not affect survival in ALS-linked mutant hSOD1 mouse models PLoS One 8 2013 e56625
143. A. Nanou, A. Higginbottom, C.F. Valori, M. Wyles, K. Ning, P. Shaw, and M. Azzouz Viral delivery of antioxidant genes as a therapeutic strategy in experimental models of amyotrophic lateral sclerosis Mol Ther 21 2013 1486 1496
144. A. Neymotin, N.Y. Calingasan, E. Wille, N. Naseri, S. Petri, M. Damiano, K.T. Liby, R. Risingsong, M. Sporn, M.F. Beal, and M. Kiaei Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis Free Radic Biol Med 51 2011 88 96
145. X. Feng, Y. Peng, M. Liu, and L. Cui DL-3-n-butylphthalide extends survival by attenuating glial activation in a mouse model of amyotrophic lateral sclerosis Neuropharmacology 62 2012 1004 1010
146. R.J. Mead, A. Higginbottom, S.P. Allen, J. Kirby, E. Bennett, S.C. Barber, P.R. Heath, A. Coluccia, N. Patel, I. Gardner, A. Brancale, A.J. Grierson, and P.J. Shaw S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis Free Radic Biol Med 61 2013 438 452
147. T. Kanno, K. Tanaka, Y. Yanagisawa, K. Yasutake, S. Hadano, F. Yoshii, N. Hirayama, and J.E. Ikeda A novel small molecule, N-(4-(2-pyridyl)(1,3-thiazol-2-yl))-2-(2,4,6-trimethylphenoxy) acetamide, selectively protects against oxidative stress-induced cell death by activating the Nrf2-ARE pathway: therapeutic implications for ALS Free Radic Biol Med 53 2012 2028 2042
148. K. Tanaka, T. Kanno, Y. Yanagisawa, K. Yasutake, S. Inoue, N. Hirayama, and J.E. Ikeda A novel acylaminoimidazole derivative, WN1316, alleviates disease progression via suppression of glial inflammation in ALS mouse model PLoS One 9 2014 e87728
149. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 1993 971 983
150. G. Bates Huntingtin aggregation and toxicity in Huntington's disease Lancet 361 2003 1642 1644
151. S.E. Browne, and M.F. Beal Oxidative damage in Huntington's disease pathogenesis Antioxid Redox Signal 8 2006 2061 2073
152. A. Johri, A. Chandra, and M.F. Beal PGC-1alpha, mitochondrial dysfunction, and Huntington's disease Free Radic Biol Med 62 2013 37 46
153. P.H. Reddy Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fission Drug Discov Today 19 2014 951 955
154. S.E. Browne, R.J. Ferrante, and M.F. Beal Oxidative stress in Huntington's disease Brain Pathol 9 1999 147 163
155. M.F. Beal, E. Brouillet, B. Jenkins, R. Henshaw, B. Rosen, and B.T. Hyman Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate J Neurochem 61 1993 1147 1150
156. C.V. Borlongan, T.K. Koutouzis, and P.R. Sanberg 3-Nitropropionic acid animal model and Huntington's disease Neurosci Biobehav Rev 21 1997 289 293
157. M.J. Calkins, R.J. Jakel, D.A. Johnson, K. Chan, Y.W. Kan, and J.A. Johnson Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription Proc Natl Acad Sci U S A 102 2005 244 249
158. M.J. Calkins, M.R. Vargas, D.A. Johnson, and J.A. Johnson Astrocyte-specific overexpression of Nrf2 protects striatal neurons from mitochondrial complex II inhibition Toxicol Sci 115 2010 557 568
159. Y. Gao, S.F. Chu, J.P. Li, Z. Zhang, J.Q. Yan, Z.L. Wen, C.Y. Xia, Z. Mou, Z.Z. Wang, W.B. He, X.F. Guo, G.N. Wei, and N.H. Chen Protopanaxtriol protects against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington's disease Acta Pharmacol Sin 36 2015 311 322
160. K. Gopinath, and G. Sudhandiran Naringin modulates oxidative stress and inflammation in 3-nitropropionic acid-induced neurodegeneration through the activation of nuclear factor-erythroid 2-related factor-2 signalling pathway Neuroscience 227 2012 134 143
161. N.M. Frederick, J. Bertho, K.K. Patel, G.T. Petr, E. Bakradze, S.B. Smith, and P.A. Rosenberg Dysregulation of system xc(-) expression induced by mutant huntingtin in a striatal neuronal cell line and in R6/2 mice Neurochem Int 76 2014 59 69
162. A.Y. Shih, S. Imbeault, V. Barakauskas, H. Erb, L. Jiang, P. Li, and T.H. Murphy Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo J Biol Chem 280 2005 22925 22936
163. M.J. Calkins, J.A. Townsend, D.A. Johnson, and J.A. Johnson Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription Exp Neurol 224 2010 307 317
164. L. Yang, N.Y. Calingasan, B. Thomas, R.K. Chaturvedi, M. Kiaei, E.J. Wille, K.T. Liby, C. Williams, D. Royce, R. Risingsong, E.S. Musiek, J.D. Morrow, M. Sporn, and M.F. Beal Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription PLoS One 4 2009 e5757
165. C. Stack, D. Ho, E. Wille, N.Y. Calingasan, C. Williams, K. Liby, M. Sporn, M. Dumont, and M.F. Beal Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease Free Radic Biol Med 49 2010 147 158
166. G. Ellrichmann, E. Petrasch-Parwez, D.H. Lee, C. Reick, L. Arning, C. Saft, R. Gold, and R.A. Linker Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease PLoS One 6 2011 e16172
167. National Multiple Sclerosis Society. 2015. 'Who Gets MS?', Accessed 15 Feb. 〈http://www.nationalmssociety.org/What-is-MS/Who-Gets-MS〉.
168. S. Dhib-Jalbut Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis Neurology 68 2007 S13-21; discussion S43-54
169. H. Hofstetter, R. Gold, and H.P. Hartung Th17 Cells in MS and Experimental Autoimmune Encephalomyelitis Int MS J 16 2009 12 18
170. V. Chiurchiu Novel targets in multiple sclerosis: to oxidative stress and beyond Curr Top Med Chem 14 2014 2590 2599
171. J. van Horssen, G. Schreibelt, L. Bo, L. Montagne, B. Drukarch, F.L. van Muiswinkel, and H.E. de Vries NAD(P)H:quinone oxidoreductase 1 expression in multiple sclerosis lesions Free Radic Biol Med 41 2006 311 317
172. J. van Horssen, G. Schreibelt, J. Drexhage, T. Hazes, C.D. Dijkstra, P. van der Valk, and H.E. de Vries Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression Free Radic Biol Med 45 2008 1729 1737
173. J. van Horssen, J.A. Drexhage, T. Flor, W. Gerritsen, P. van der Valk, and H.E. de Vries Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions Free Radic Biol Med 49 2010 1283 1289
174. D.A. Johnson, S. Amirahmadi, C. Ward, Z. Fabry, and J.A. Johnson The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis Toxicol Sci 114 2010 237 246
175. R.A. Linker, D.H. Lee, S. Ryan, A.M. van Dam, R. Conrad, P. Bista, W. Zeng, X. Hronowsky, A. Buko, S. Chollate, G. Ellrichmann, W. Bruck, K. Dawson, S. Goelz, S. Wiese, R.H. Scannevin, M. Lukashev, and R. Gold Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway Brain 134 2011 678 692
176. T.K. Pareek, A. Belkadi, S. Kesavapany, A. Zaremba, S.L. Loh, L. Bai, M.L. Cohen, C. Meyer, K.T. Liby, R.H. Miller, M.B. Sporn, and J.J. Letterio Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis Sci Rep 1 2011 201
177. B. Li, W. Cui, J. Liu, R. Li, Q. Liu, X.H. Xie, X.L. Ge, J. Zhang, X.J. Song, Y. Wang, and L. Guo Sulforaphane ameliorates the development of experimental autoimmune encephalomyelitis by antagonizing oxidative stress and Th17-related inflammation in mice Exp Neurol 250 2013 239 249
178. N. Liu, Q.C. Kan, X.J. Zhang, Y.M. Xv, S. Zhang, G.X. Zhang, and L. Zhu Upregulation of immunomodulatory molecules by matrine treatment in experimental autoimmune encephalomyelitis Exp Mol Pathol 97 2014 470 476
179. S. Schilling, S. Goelz, R. Linker, F. Luehder, and R. Gold Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration Clin Exp Immunol 145 2006 101 107
180. T.H. Murphy, J. Yu, R. Ng, D.A. Johnson, H. Shen, C.R. Honey, and J.A. Johnson Preferential expression of antioxidant response element mediated gene expression in astrocytes J Neurochem 76 2001 1670 1678
181. K. Takaya, T. Suzuki, H. Motohashi, K. Onodera, S. Satomi, T.W. Kensler, and M. Yamamoto Validation of the multiple sensor mechanism of the Keap1-Nrf2 system Free Radic Biol Med 53 2012 817 827
182. R.H. Scannevin, S. Chollate, M.Y. Jung, M. Shackett, H. Patel, P. Bista, W. Zeng, S. Ryan, M. Yamamoto, M. Lukashev, and K.J. Rhodes Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway J Pharmacol Exp Ther 341 2012 274 284
183. I. Metz, S. Traffehn, K. Strassburger-Krogias, K. Keyvani, M. Bergmann, K. Nolte, M.S. Weber, T. Bartsch, R. Gold, and W. Bruck Glial cells express nuclear nrf2 after fumarate treatment for multiple sclerosis and psoriasis Neurol Neuroimmunol Neuroinflamm 2 2015 e99
184. M.L. Block, L. Zecca, and J.S. Hong Microglia-mediated neurotoxicity: uncovering the molecular mechanisms Nat Rev Neurosci 8 2007 57 69
185. A.I. Rojo, G. McBean, M. Cindric, J. Egea, M.G. Lopez, P. Rada, N. Zarkovic, and A. Cuadrado Redox control of microglial function: molecular mechanisms and functional significance Antioxid Redox Signal 21 2014 1766 1801
186. L.J. Lawson, V.H. Perry, P. Dri, and S. Gordon Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain Neuroscience 39 1990 151 170
187. M.E. Lull, and M.L. Block Microglial activation and chronic neurodegeneration Neurotherapeutics 7 2010 354 365
188. M.L. Block, and J.S. Hong Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism Prog Neurobiol 76 2005 77 98
189. N.G. Innamorato, A.I. Rojo, A.J. Garcia-Yague, M. Yamamoto, M.L. de Ceballos, and A. Cuadrado The transcription factor Nrf2 is a therapeutic target against brain inflammation J Immunol 181 2008 680 689
190. X. Wang, J.P. de Rivero Vaccari, H. Wang, P. Diaz, R. German, A.E. Marcillo, and R.W. Keane Activation of the nuclear factor E2-related factor 2/antioxidant response element pathway is neuroprotective after spinal cord injury J Neurotrauma 29 2012 936 945
191. I. Lastres-Becker, N.G. Innamorato, T. Jaworski, A. Rabano, S. Kugler, F. Van Leuven, and A. Cuadrado Fractalkine activates Nrf2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis Brain 137 2014 78 91
192. E. Li, M. Noda, Y. Doi, B. Parajuli, J. Kawanokuchi, Y. Sonobe, H. Takeuchi, T. Mizuno, and A. Suzumura The neuroprotective effects of milk fat globule-EGF factor 8 against oligomeric amyloid beta toxicity' J Neuroinflammation 9 2012 148
193. A. LoGerfo, L. Chico, L. Borgia, L. Petrozzi, A. Rocchi, A.D. Amelio, C. Carlesi, E. Caldarazzo Ienco, M. Mancuso, and G. Siciliano Lack of association between nuclear factor erythroid-derived 2-like 2 promoter gene polymorphisms and oxidative stress biomarkers in amyotrophic lateral sclerosis patients Oxid Med Cell Longev 2014 2014 432626
194. M. von Otter, S. Landgren, S. Nilsson, D. Celojevic, P. Bergstrom, A. Hakansson, H. Nissbrandt, M. Drozdzik, M. Bialecka, M. Kurzawski, K. Blennow, M. Nilsson, O. Hammarsten, and H. Zetterberg Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease BMC Med Genet 11 2010 36
195. M. von Otter, P. Bergstrom, A. Quattrone, E.V. De Marco, G. Annesi, P. Soderkvist, S.B. Wettinger, M. Drozdzik, M. Bialecka, H. Nissbrandt, C. Klein, M. Nilsson, O. Hammarsten, S. Nilsson, and H. Zetterberg Genetic associations of Nrf2-encoding NFE2L2 variants with Parkinson's disease-a multicenter study BMC Med Genet, 1 5: 13 2014 1
196. Y.C. Chen, Y.R. Wu, Y.C. Wu, G.J. Lee-Chen, and C.M. Chen Genetic analysis of NFE2L2 promoter variation in Taiwanese Parkinson's disease Parkinsonism Relat Disord 19 2013 247 250
197. M. von Otter, S. Landgren, S. Nilsson, M. Zetterberg, D. Celojevic, P. Bergstrom, L. Minthon, N. Bogdanovic, N. Andreasen, D.R. Gustafson, I. Skoog, A. Wallin, G. Tasa, K. Blennow, M. Nilsson, O. Hammarsten, and H. Zetterberg Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract Mech Ageing Dev 131 2010 105 110
198. P. Bergstrom, M. von Otter, S. Nilsson, A.C. Nilsson, M. Nilsson, P.M. Andersen, O. Hammarsten, and H. Zetterberg Association of NFE2L2 and Keap1 haplotypes with amyotrophic lateral sclerosis Amyotroph Lateral Scler Frontotemporal Degener 15 2014 130 137
199. L. Wang, T. Lewis, Y.L. Zhang, C. Khodier, S. Magesh, L. Chen, D. Inoyama, Y. Chen, J. Zhen, L. Hu, L.J. Beamer, P.W. Faloon, S. Dandapani, J.R. Perez, B. Munoz, M. Palmer, and S. Schreiber ''The identification and characterization of non-reactive inhibitor of Keap1-Nrf2 interaction through HTS using a fluorescence polarization assay.' in, Probe Reports from the NIH Molecular Libraries Program (Bethesda (MD)) 2010 [PubMed PMID:24260785]
200. T.P. Williamson, S. Amirahmadi, G. Joshi, N.K. Kaludov, M.N. Martinov, D.A. Johnson, and J.A. Johnson Discovery of potent, novel Nrf2 inducers via quantum modeling, virtual screening, and in vitro experimental validation Chem Biol Drug Des 80 2012 810 820
201. K.C. Wu, P.R. McDonald, J.J. Liu, R. Chaguturu, and C.D. Klaassen Implementation of a high-throughput screen for identifying small molecules to activate the Keap1-Nrf2-ARE pathway PLoS One 7 2012 e44686
202. M. Schaap, R. Hancock, A. Wilderspin, and G. Wells Development of a steady-state FRET-based assay to identify inhibitors of the Keap1-Nrf2 protein-protein interaction Protein Sci 22 2013 1812 1819
203. R. Wang, D.E. Mason, K.P. Choe, A.S. Lewin, E.C. Peters, and H. Luesch In vitro and in vivo characterization of a tunable dual-reactivity probe of the Nrf2-ARE pathway ACS Chem Biol 8 2013 1764 1774
204. T. Shen, X.M. Chen, B. Harder, M. Long, X.N. Wang, H.X. Lou, G.T. Wondrak, D.M. Ren, and D.D. Zhang Plant extracts of the family Lauraceae: a potential resource for chemopreventive agents that activate the nuclear factor-erythroid 2-related factor 2/antioxidant response element pathway Planta Med 80 2014 426 434
205. S.C. van der Linden, A.R. von Bergh, B.M. van Vught-Lussenburg, L.R. Jonker, M. Teunis, C.A. Krul, and B. van der Burg Development of a panel of high-throughput reporter-gene assays to detect genotoxicity and oxidative stress Mutat Res Genet Toxicol Environ Mutagen 760 2014 23 32
206. R. Hancock, H.C. Bertrand, T. Tsujita, S. Naz, A. El-Bakry, J. Laoruchupong, J.D. Hayes, and G. Wells Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction Free Radic Biol Med 52 2012 444 451
207. C. Zhuang, Z. Miao, C. Sheng, and W. Zhang Updated Research and Applications of Small Molecule Inhibitors of Keap1-Nrf2 Protein-Protein Interaction: a Review Curr Med Chem. 2014
208. D. de Zeeuw, T. Akizawa, P. Audhya, G.L. Bakris, M. Chin, H. Christ-Schmidt, A. Goldsberry, M. Houser, M. Krauth, H.J. Lambers Heerspink, J.J. McMurray, C.J. Meyer, H.H. Parving, G. Remuzzi, R.D. Toto, N.D. Vaziri, C. Wanner, J. Wittes, D. Wrolstad, G.M. Chertow, and Beacon Trial Investigators Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease N Engl J Med 369 2013 2492 2503
209. S.A. Reisman, K.W. Ward, C.D. Klaassen, and C.J. Meyer CDDO-9,11-dihydro-trifluoroethyl amide (CDDO-dhTFEA) induces hepatic cytoprotective genes and increases bile flow in rats Xenobiotica 43 2013 571 578
210. B. Li, A. Abdalrahman, Y. Lai, J.S. Janicki, K.W. Ward, C.J. Meyer, X.L. Wang, D. Tang, and T. Cui Dihydro-CDDO-trifluoroethyl amide suppresses inflammatory responses in macrophages via activation of Nrf2 Biochem Biophys Res Commun 444 2014 555 561
211. S.A. Reisman, C.Y. Lee, C.J. Meyer, J.W. Proksch, and K.W. Ward Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin Arch Dermatol Res 306 2014 447 454
212. B.L. Probst, I. Trevino, L. McCauley, R. Bumeister, I. Dulubova, W.C. Wigley, and D.A. Ferguson RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity PLoS One 10 2015 e0122942
213. J.C. Tobon-Velasco, G. Vazquez-Victorio, M. Macias-Silva, E. Cuevas, S.F. Ali, P.D. Maldonado, M.E. Gonzalez-Trujano, A. Cuadrado, J. Pedraza-Chaverri, and A. Santamaria S-allyl cysteine protects against 6-hydroxydopamine-induced neurotoxicity in the rat striatum: involvement of Nrf2 transcription factor activation and modulation of signaling kinase cascades Free Radic Biol Med 53 2012 1024 1040
214. E. Garcia, R. Santana-Martinez, C.A. Silva-Islas, A.L. Colin-Gonzalez, S. Galvan-Arzate, Y. Heras, P.D. Maldonado, J. Sotelo, and A. Santamaria S-allyl cysteine protects against MPTP-induced striatal and nigral oxidative neurotoxicity in mice: participation of Nrf2 Free Radic Res 48 2014 159 167
215. T.P. Williamson, D.A. Johnson, and J.A. Johnson Activation of the Nrf2-ARE pathway by siRNA knockdown of Keap1 reduces oxidative stress and provides partial protection from MPTP-mediated neurotoxicity Neurotoxicology 33 2012 272 279
216. M. Galuppo, R. Iori, G.R. De Nicola, P. Bramanti, and E. Mazzon Anti-inflammatory and anti-apoptotic effects of (RS)-glucoraphanin bioactivated with myrosinase in murine sub-acute and acute MPTP-induced Parkinson's disease Bioorg Med Chem 21 2013 5532 5547
217. J. Ryu, R. Zhang, B.H. Hong, E.J. Yang, K.A. Kang, M. Choi, K.C. Kim, S.J. Noh, H.S. Kim, N.H. Lee, J.W. Hyun, and H.S. Kim Phloroglucinol attenuates motor functional deficits in an animal model of Parkinson's disease by enhancing Nrf2 activity PLoS One 8 2013 e71178
218. H. Lou, X. Jing, X. Wei, H. Shi, D. Ren, and X. Zhang Naringenin protects against 6-OHDA-induced neurotoxicity via activation of the Nrf2/ARE signaling pathway Neuropharmacology 79 2014 380 388
219. X.L. Wang, G.H. Xing, B. Hong, X.M. Li, Y. Zou, X.J. Zhang, and M.X. Dong Gastrodin prevents motor deficits and oxidative stress in the MPTP mouse model of Parkinson's disease: involvement of ERK1/2-Nrf2 signaling pathway Life Sci 114 2014 77 85
220. S.Y. Woo, J.H. Kim, M.K. Moon, S.H. Han, S.K. Yeon, J.W. Choi, B.K. Jang, H.J. Song, Y.G. Kang, J.W. Kim, J. Lee, D.J. Kim, O. Hwang, and K.D. Park Discovery of vinyl sulfones as a novel class of neuroprotective agents toward Parkinson's disease therapy J Med Chem 57 2014 1473 1487
221. J.A. Lee, J.H. Kim, S.Y. Woo, H.J. Son, S.H. Han, B.K. Jang, J.W. Choi, D.J. Kim, K.D. Park, and O. Hwang A novel compound VSC2 has anti-inflammatory and antioxidant properties in microglia and in Parkinson's disease animal model Br J Pharmacol 172 2015 1087 1100
222. X. Jing, H. Shi, C. Zhang, M. Ren, M. Han, X. Wei, X. Zhang, and H. Lou Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson's disease by enhancing Nrf2 activity Neuroscience 286 2015 131 140
223. H.J. Son, J.H. Choi, J.A. Lee, D.J. Kim, K.J. Shin, and O. Hwang Induction of NQO1 and Neuroprotection by a Novel Compound KMS04014 in Parkinson's Disease Models J Mol Neurosci. 2015
224. Z. Zhang, G. Li, S.S. Szeto, C. Chong, Q. Quan, C. Huang, W. Cui, B. Guo, Y. Wang, Y. Han, K.W. Michael Siu, S.M. Yuen Lee, and I.K. Chu Examining the neuroprotective effects of protocatechuic acid and chrysin on in vitro and in vivo models of Parkinson disease Free Radic Biol Med. 84 2015 331 343
225. Y.F. Zhao, Q. Zhang, J.Y. Xi, Y.H. Li, C.G. Ma, and B.G. Xiao Multitarget intervention of Fasudil in the neuroprotection of dopaminergic neurons in MPTP-mouse model of Parkinson's disease J Neurol Sci. 2015
226. D.R. Marshak, S.A. Pesce, L.C. Stanley, and W.S. Griffin Increased S100 beta neurotrophic activity in Alzheimer's disease temporal lobe Neurobiol Aging 13 1992 1 7
227. H.M. Schipper, D.A. Bennett, A. Liberman, J.L. Bienias, J.A. Schneider, J. Kelly, and Z. Arvanitakis Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment Neurobiol Aging 27 2006 252 261
228. S.S. Shaftel, W.S. Griffin, and M.K. O'Banion The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective J Neuroinflammation 5 2008 7
229. X. Wang, B. Su, G. Perry, M.A. Smith, and X. Zhu Insights into amyloid-beta-induced mitochondrial dysfunction in Alzheimer disease Free Radic Biol Med 43 2007 1569 1573